CD274 and non-small cell lung carcinoma: Moreover, 4 NSCLC trials (1,672 patients; 73.2% men and 26.8 women) evaluated pooled OS-HR of PD1/PD-L1 ICI vs chemotherapy, resulting higher risk for females (13) Women also experience more immunotherapy AE (33).This data suggests a significant benefit of ICIs in males.